MX2016004329A - Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. - Google Patents
Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.Info
- Publication number
- MX2016004329A MX2016004329A MX2016004329A MX2016004329A MX2016004329A MX 2016004329 A MX2016004329 A MX 2016004329A MX 2016004329 A MX2016004329 A MX 2016004329A MX 2016004329 A MX2016004329 A MX 2016004329A MX 2016004329 A MX2016004329 A MX 2016004329A
- Authority
- MX
- Mexico
- Prior art keywords
- benralizumab
- methods
- chronic obstructive
- obstructive pulmonary
- treating chronic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361891175P | 2013-10-15 | 2013-10-15 | |
| US201461970126P | 2014-03-25 | 2014-03-25 | |
| PCT/US2014/060432 WO2015057668A1 (en) | 2013-10-15 | 2014-10-14 | Methods for treating chronic obstructive pulmonary disease using benralizumab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016004329A true MX2016004329A (es) | 2016-11-10 |
Family
ID=52809872
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004329A MX2016004329A (es) | 2013-10-15 | 2014-10-14 | Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. |
| MX2019013468A MX2019013468A (es) | 2013-10-15 | 2016-04-04 | Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013468A MX2019013468A (es) | 2013-10-15 | 2016-04-04 | Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20150104447A1 (enExample) |
| EP (2) | EP3057609A4 (enExample) |
| JP (3) | JP2016534996A (enExample) |
| KR (1) | KR20160061352A (enExample) |
| CN (2) | CN105636607A (enExample) |
| AU (2) | AU2014334563A1 (enExample) |
| BR (1) | BR112016008082A2 (enExample) |
| CA (1) | CA2925402A1 (enExample) |
| MX (2) | MX2016004329A (enExample) |
| RU (1) | RU2706729C2 (enExample) |
| SG (2) | SG10201807318RA (enExample) |
| WO (1) | WO2015057668A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2904805A1 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| CA2904806C (en) | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
| CN110981957B (zh) | 2014-01-15 | 2024-12-24 | 豪夫迈·罗氏有限公司 | 具有改善的蛋白A结合作用的Fc区变体 |
| AU2016272399B2 (en) | 2015-06-01 | 2021-09-09 | Kyowa Kirin Co., Ltd. | Therapeutic agent and therapeutic method for pulmonary hypertension |
| CN109544378B (zh) * | 2018-10-27 | 2024-06-25 | 平安医疗健康管理股份有限公司 | 一种肺源性心脏病资质认证方法、设备及服务器 |
| TW202110479A (zh) * | 2019-05-16 | 2021-03-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法 |
| CN114786775A (zh) * | 2019-12-06 | 2022-07-22 | 赛诺菲生物技术公司 | 通过施用il-33拮抗剂治疗copd的方法 |
| EP3957308A1 (en) * | 2020-08-21 | 2022-02-23 | Palobiofarma, S.L. | (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases |
| WO2023034993A1 (en) * | 2021-09-03 | 2023-03-09 | Gleich Gerald J | Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2233974T3 (es) | 1995-09-11 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana. |
| EP2275540B1 (en) * | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| WO2001060405A1 (en) * | 2000-02-15 | 2001-08-23 | Kyowa Hakko Kogyo Co., Ltd. | Eosinophil-specific apoptosis inducer |
| US6946292B2 (en) * | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US8093357B2 (en) * | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20060014680A1 (en) * | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| PT3072525T (pt) * | 2007-05-14 | 2018-04-20 | Astrazeneca Ab | Métodos para reduzir os níveis de basófilos |
| CN101249093A (zh) * | 2008-03-19 | 2008-08-27 | 李虎山 | 一种治疗慢性阻塞性肺部疾病的组合物 |
| PL2627673T3 (pl) * | 2010-10-15 | 2018-01-31 | Medimmune Ltd | Terapie poprawiające funkcje płuc |
| KR101615420B1 (ko) * | 2010-12-16 | 2016-04-26 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
| WO2012158954A1 (en) * | 2011-05-18 | 2012-11-22 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
| CN104039352A (zh) * | 2011-11-01 | 2014-09-10 | 米迪缪尼有限公司 | 用于降低哮喘急性恶化的频率和严重性的方法 |
| SMT201900311T1 (it) * | 2013-08-12 | 2019-07-11 | Astrazeneca Ab | Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab |
| CA2918105C (en) * | 2013-08-12 | 2023-02-28 | Medimmune, Llc | Methods for reducing exacerbation rates of asthma using benralizumab |
| BR112016002462A8 (pt) * | 2013-08-12 | 2018-06-12 | Medimmune Llc | Métodos para melhorar os sintomas da asma usando benralizumabe |
-
2014
- 2014-10-14 SG SG10201807318RA patent/SG10201807318RA/en unknown
- 2014-10-14 US US14/513,866 patent/US20150104447A1/en not_active Abandoned
- 2014-10-14 EP EP14853201.3A patent/EP3057609A4/en not_active Withdrawn
- 2014-10-14 RU RU2016118425A patent/RU2706729C2/ru active
- 2014-10-14 KR KR1020167009675A patent/KR20160061352A/ko not_active Ceased
- 2014-10-14 JP JP2016523209A patent/JP2016534996A/ja active Pending
- 2014-10-14 BR BR112016008082A patent/BR112016008082A2/pt not_active Application Discontinuation
- 2014-10-14 CA CA2925402A patent/CA2925402A1/en not_active Abandoned
- 2014-10-14 CN CN201480056549.0A patent/CN105636607A/zh active Pending
- 2014-10-14 MX MX2016004329A patent/MX2016004329A/es unknown
- 2014-10-14 WO PCT/US2014/060432 patent/WO2015057668A1/en not_active Ceased
- 2014-10-14 CN CN202110508239.XA patent/CN113230399A/zh active Pending
- 2014-10-14 EP EP18189626.7A patent/EP3485902A1/en not_active Withdrawn
- 2014-10-14 AU AU2014334563A patent/AU2014334563A1/en not_active Abandoned
- 2014-10-14 SG SG11201601807XA patent/SG11201601807XA/en unknown
-
2016
- 2016-04-04 MX MX2019013468A patent/MX2019013468A/es unknown
- 2016-05-31 US US15/168,711 patent/US20170107291A1/en not_active Abandoned
-
2017
- 2017-11-29 US US15/825,526 patent/US20180291108A1/en not_active Abandoned
-
2019
- 2019-05-24 US US16/422,212 patent/US20200123262A1/en not_active Abandoned
- 2019-07-18 JP JP2019132432A patent/JP6870037B2/ja active Active
-
2020
- 2020-04-02 AU AU2020202333A patent/AU2020202333A1/en not_active Abandoned
-
2021
- 2021-04-14 JP JP2021068065A patent/JP2021107421A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20150104447A1 (en) | 2015-04-16 |
| JP2021107421A (ja) | 2021-07-29 |
| US20180291108A1 (en) | 2018-10-11 |
| SG10201807318RA (en) | 2018-09-27 |
| RU2706729C2 (ru) | 2019-11-20 |
| CN113230399A (zh) | 2021-08-10 |
| CN105636607A (zh) | 2016-06-01 |
| JP2016534996A (ja) | 2016-11-10 |
| EP3057609A1 (en) | 2016-08-24 |
| RU2016118425A3 (enExample) | 2018-07-19 |
| WO2015057668A1 (en) | 2015-04-23 |
| MX2019013468A (es) | 2020-02-12 |
| EP3057609A4 (en) | 2017-03-22 |
| JP2019203009A (ja) | 2019-11-28 |
| AU2014334563A1 (en) | 2016-04-07 |
| JP6870037B2 (ja) | 2021-05-12 |
| KR20160061352A (ko) | 2016-05-31 |
| RU2016118425A (ru) | 2017-11-21 |
| US20170107291A1 (en) | 2017-04-20 |
| AU2020202333A1 (en) | 2020-04-23 |
| BR112016008082A2 (pt) | 2017-10-17 |
| EP3485902A1 (en) | 2019-05-22 |
| US20200123262A1 (en) | 2020-04-23 |
| CA2925402A1 (en) | 2015-04-23 |
| SG11201601807XA (en) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019013468A (es) | Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. | |
| PH12015502075A1 (en) | Treatment of cataplexy | |
| MX2023000079A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento de sinusitis cronica con polipos nasales. | |
| MX2016002826A (es) | Anticuerpos anti-b7-h1 para tratar tumores. | |
| PL3791896T3 (pl) | Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu | |
| PH12015501108B1 (en) | Treatment of pulmonary disease | |
| EA201891833A1 (ru) | Комбинация для лечения амиотрофического бокового склероза или родственных болезней | |
| ES2765949T8 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
| MX2015017970A (es) | Metodos para tratar la poliposis nasal mediante la administracion de un antagonista de il-4r. | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| NZ710726A (en) | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide | |
| EA201990684A1 (ru) | Способы применения оксигенированных холестеролсульфатов (ocs) | |
| MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
| MX2016001383A (es) | Metodos para reducir la tasa de exacerbacion de asma mediante el uso de benralizumab. | |
| EA201491286A1 (ru) | Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину | |
| EA201590883A1 (ru) | Лечение помалидомидом рака у субъекта с почечной недостаточностью | |
| NZ629828A (en) | Methods for the treatment of b cell-mediated inflammatory diseases | |
| MX2015013066A (es) | Usos terapéuticos para anticuerpos contra vegfr1. | |
| MX2016001195A (es) | Metodos para mejorar sintomas de asma mediante el uso de benralizumab. | |
| MX2016001384A (es) | Metodos para incrementar el volumen espiratorio forzado en pacientes asmaticos que usan benralizumab. | |
| EA201792282A1 (ru) | Способы лечения заболеваний | |
| MX2014001764A (es) | Inhibidor de alfa1-proteinasa para demorar el comienzo o progresion de exacerbaciones pulmonares. | |
| EA201491581A1 (ru) | Везикулярные композиции | |
| EA201690446A1 (ru) | Лечение множественной миеломы | |
| EA201690445A1 (ru) | Лечение рака |